
Italian pharma group Recordati has paid $80 million to Lundbeck for a portfolio of products primarily aimed at the US …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

